A total of 167 drug samples flagged as 'not of standard quality' in December 2025: Health Ministry

The recent report from the Health Ministry, flagging 167 drug samples as 'not of standard quality' (NSQ) in December 2025, serves as a critical reminder of the persistent challenges in ensuring drug safety and quality in India. This routine regulatory surveillance, conducted by the Central Drugs Standard Control Organisation (CDSCO), is a cornerstone of India's public health infrastructure, yet such findings underscore the continuous need for vigilance and reform in the pharmaceutical sector. **Background Context and What Happened:** India is globally recognized as the 'pharmacy of the world,' being the largest provider of generic drugs globally. This distinction, however, comes with immense responsibility to maintain stringent quality standards. The Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945, form the primary legislative framework governing drug manufacturing, sale, and distribution in the country. The CDSCO, under the Ministry of Health and Family Welfare, is the central regulatory authority responsible for approving new drugs, conducting clinical trials, setting standards, and ensuring quality control through post-market surveillance. The news article highlights a regular activity: the monthly publication of NSQ and spurious drug lists on the CDSCO portal. The 167 samples identified as NSQ mean they failed to meet specified quality parameters, which could range from sub-potency (less active ingredient than stated), contamination, incorrect labeling, or other deviations from prescribed standards. **Key Stakeholders Involved:** Several key stakeholders are critically involved. Firstly, the **Health Ministry** and **CDSCO** are at the forefront, responsible for policy formulation, standard-setting, and enforcement. **State Drug Control Authorities** play a crucial role in licensing, inspection, and enforcement at the state level. **Pharmaceutical Manufacturers** bear the primary responsibility for adhering to Good Manufacturing Practices (GMP) and ensuring the quality of their products. **Healthcare Professionals** (doctors, pharmacists) are responsible for prescribing and dispensing quality medicines and reporting adverse drug reactions. Finally, **Consumers** are the ultimate beneficiaries and, unfortunately, often the victims of substandard drugs, making their right to safe medication paramount. **Why This Matters for India:** This issue holds profound significance for India. From a public health perspective, NSQ drugs can lead to treatment failures, prolonged illness, increased healthcare costs, and even death. For instance, sub-potent antibiotics can fuel antimicrobial resistance (AMR), a growing global health crisis. Economically, India's reputation as a reliable supplier of affordable, quality medicines is crucial for its export market. Incidents of NSQ drugs can severely damage this trust, affecting trade relations and the livelihood of millions employed in the pharmaceutical sector. Socially, the availability of substandard drugs erodes public trust in the healthcare system and government regulatory bodies, particularly impacting vulnerable populations who may not have access to alternative treatments. This directly touches upon the spirit of **Article 21 of the Indian Constitution**, which guarantees the 'Right to Life' – implicitly encompassing the right to health and access to safe and effective medication. **Historical Context:** The journey of drug regulation in India began even before independence with the recommendations of the Drugs Enquiry Committee (1930) leading to the Drugs and Cosmetics Act of 1940. Over the decades, this act has been amended multiple times to adapt to scientific advancements, global standards, and emerging challenges. The establishment of CDSCO and its functions have evolved to include more rigorous approval processes, inspection mechanisms, and post-market surveillance. Despite these efforts, challenges like inadequate testing infrastructure, manpower shortages in regulatory bodies, and unethical practices by some manufacturers persist. **Future Implications:** Addressing the challenge of NSQ drugs requires a multi-pronged approach. Future implications include a push for stricter enforcement of GMP, potentially through more frequent and unannounced inspections. There will likely be an increased investment in upgrading testing laboratories and enhancing the technical capabilities of regulatory personnel. The government may also explore leveraging technology, such as track-and-trace systems, to prevent counterfeiting and ensure supply chain integrity. Furthermore, greater transparency in reporting NSQ drugs and punitive actions against non-compliant manufacturers are crucial. This will not only safeguard public health but also bolster India's standing as a responsible global pharmaceutical player, aligning with the goals of the **National Health Policy 2017** which emphasizes quality and access to medicines. In essence, the identification of NSQ drugs is not merely a statistical anomaly but a call to action for continuous improvement in India's drug regulatory framework and manufacturing practices. It underscores the ongoing commitment required from all stakeholders to uphold the highest standards of quality and safety for the health of the nation and beyond.